Live Breaking News & Updates on கட்டி திசு

Stay updated with breaking news from கட்டி திசு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Tagrisso approved in China in early lung cancer


 
of
patients with early-stage EGFR-mutated lung cancer
 
Tagrisso is the only targeted medicine to show efficacy in the treatment of early-stage lung cancer in a global trial and the first such medicine approved in China
 
where Tagrisso reduced the risk of disease recurrence or death by 80%
 
AstraZeneca s Tagrisso (osimertinib) has been approved in China for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumour resection with curative intent, with or without adjuvant chemotherapy as recommended by the patient s physician. Tagrisso is indicated for EGFRm patients whose tumours have exon 19 deletions or exon 21 (L858R) mutations. ....

United Kingdom , United States , Dave Fredrickson , Thorac Onc , Astrazeneca Tagrisso , Adrian Kemp , Le Chevalier , Collaborative Group , Company On Twitter , Single Institution Study , World Health Organization , Data Monitoring Committee , Archives Pathology Lab , Lungevity Foundation , National Reimbursement Drug List , China National Medical Products Administration , Investor Relations Team , International Agency For Research On Cancer , National Medical Products Administration , Executive Vice President , Oncology Business Unit , New England Journal , National Reimbursement Drug , South America , Independent Data Monitoring Committee , Cancer Biomarkers ,